CTOs on the Move

Beam Therapeutics

www.beamtx.com

 
Beam Therapeutics, launched in 2018, is pioneering the use of CRISPR base editing to develop a broad portfolio of advanced genetic medicines. Our groundbreaking base editing technology allows us to make permanent, specific edits to single bases in DNA and RNA, without cutting the strands. Base editor therapeutics represent a new class of “precision genetic medicines,” combining precision targeting of the genome with precision control of editing outcomes. Our dream is to provide life-long cures for patients suffering from serious diseases. The Beam Team Is: • A community of fearless innovators • Rigorous and honest in our research • Listening ...
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.beamtx.com
  • 26 Landsdowne Street 2nd Floor
    Cambridge, MA USA 02139
  • Phone: 857.327.8775

Executives

Name Title Contact Details
Nicholas Meghri
 Associate Director, IT Business Partnership Profile
Brian Riley
 Senior Vice President of Technical Operations Profile
Brad Dutot
 Vice President, Information Technology Profile

Funding

Beam Therapeutics raised $13M on 04/27/2018
Beam Therapeutics raised $74M on 05/14/2018
Beam Therapeutics raised $11M on 03/06/2019
Beam Therapeutics raised $260M on 01/19/2021

Similar Companies

Commonwealth Biotechnologies

Commonwealth Biotechnologies is a Richmond, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sterling Pharma Solutions

Sterling is a CDMO or contract development and manufacturing organisation (/contract manufacturer organisation) with facilities in the UK and US.

Biotechlogic

Biotechlogic is a Glenview, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tobira Therapeutics

Tobira Therapeutics is a clinical-stage biopharmaceutical company developing cenicriviroc (CVC), an oral potent dual inhibitor of chemokine receptors CCR2 and CCR5. Tobira is initiating a Phase 2 clinical trial of cenicriviroc for the treatment of Nonalcoholic Steatohepatitis (NASH), a leading cause of cirrhosis and liver transplant. The company has also completed a Phase 2b clinical trial of cenicriviroc in 143 HIV-infected subjects, and the compound is positioned for Phase 3 studies as a novel, once daily, fixed-dose cenicriviroc/lamivudine backbone as part of combination HIV therapy. Tobira is backed by a syndicate of leading life science investors including Domain Associates, Frazier Healthcare Ventures, Montreux Equity Partners, Novo Ventures and Canaan Partners.

ETHEX

ETHEX Corp. is a Bridgeton, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.